FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947220160> ?p ?o ?g. }

• W2947220160 endingPage "6084" @default.
• W2947220160 startingPage "6084" @default.
• W2947220160 abstract "6084 Background: R/M ACC is a malignant neoplasm most commonly of salivary gland origin with no standard treatment. The impact of combined PD-1/CTLA-4 checkpoint blockade in R/M ACC is unknown. Methods: In a two-stage minimax phase II trial, pts with progressive R/M ACC (non-salivary primaries allowed) were enrolled and treated with nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks (1 cycle = 6 weeks). Imaging, using RECIST v1.1 response assessment, was scheduled to be performed approximately every 12 weeks. The primary endpoint was overall response rate (ORR = complete response [CR]+partial response [PR]) per RECIST v1.1. To detect a difference between an unacceptable ORR of 5% and a desirable ORR of 20% (one-sided type I error of 10%, power of 90%), at least 1 in the first 18 pts required an observed response. At least 4 responses of 32 total pts were needed to meet the primary endpoint. Treatment beyond progression of disease (PD) was allowed at the discretion of the investigator. A second cohort of pts with non-ACC salivary cancer is still accruing for separate analysis. Results: From 6/12/2017-6/20/2018, 32 pts were enrolled and evaluable for the primary endpoint. There was 1 confirmed PR in the first 18 pts, therefore enrollment of the second stage continued. ORR was 6% (2/32). One additional pt had an unconfirmed PR (-31% regression before CNS PD). For best overall response, there were 2 PRs, 15 SD, and 11 PD. Four pts never reached a first disease assessment: 3 due to death from clinical PD and 1 was removed for toxicity. Six pts discontinued the trial for toxicities (Grade 4 (G4) neutropenia/sepsis and G3 adrenal insufficiency (1), G2 hypophysitis (2), G3 arthritis > 7 days (1), G3 colitis (1), and G3 hepatitis/G4 creatinine kinase (CK) elevation (1)). The 2 confirmed PRs consisted of -73.1% and -58.4% regressions, with a duration of therapy of 18.4 and 7.8 months, respectively (treatment ongoing for both). Conclusions: The study did not meet its primary endpoint, though the responses observed were dramatic. Paired biopsy and peripheral blood samples will be analyzed to elucidate insights into mechanisms of response and resistance to dual checkpoint blockade. Clinical trial information: NCT03172624." @default.
• W2947220160 created "2019-06-07" @default.
• W2947220160 creator A5005775817 @default.
• W2947220160 creator A5011622385 @default.
• W2947220160 creator A5015195078 @default.
• W2947220160 creator A5024691456 @default.
• W2947220160 creator A5024957945 @default.
• W2947220160 creator A5026148495 @default.
• W2947220160 creator A5036572642 @default.
• W2947220160 creator A5041586147 @default.
• W2947220160 creator A5051352132 @default.
• W2947220160 creator A5052154004 @default.
• W2947220160 creator A5053307625 @default.
• W2947220160 creator A5061365371 @default.
• W2947220160 creator A5071357841 @default.
• W2947220160 creator A5084443648 @default.
• W2947220160 date "2019-05-20" @default.
• W2947220160 modified "2023-09-23" @default.
• W2947220160 title "A phase II trial cohort of nivolumab plus ipilimumab in patients (Pts) with recurrent/metastatic adenoid cystic carcinoma (R/M ACC)." @default.
• W2947220160 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.6084" @default.
• W2947220160 hasPublicationYear "2019" @default.
• W2947220160 type Work @default.
• W2947220160 sameAs 2947220160 @default.
• W2947220160 citedByCount "28" @default.
• W2947220160 countsByYear W29472201602019 @default.
• W2947220160 countsByYear W29472201602020 @default.
• W2947220160 countsByYear W29472201602021 @default.
• W2947220160 countsByYear W29472201602022 @default.
• W2947220160 countsByYear W29472201602023 @default.
• W2947220160 crossrefType "journal-article" @default.
• W2947220160 hasAuthorship W2947220160A5005775817 @default.
• W2947220160 hasAuthorship W2947220160A5011622385 @default.
• W2947220160 hasAuthorship W2947220160A5015195078 @default.
• W2947220160 hasAuthorship W2947220160A5024691456 @default.
• W2947220160 hasAuthorship W2947220160A5024957945 @default.
• W2947220160 hasAuthorship W2947220160A5026148495 @default.
• W2947220160 hasAuthorship W2947220160A5036572642 @default.
• W2947220160 hasAuthorship W2947220160A5041586147 @default.
• W2947220160 hasAuthorship W2947220160A5051352132 @default.
• W2947220160 hasAuthorship W2947220160A5052154004 @default.
• W2947220160 hasAuthorship W2947220160A5053307625 @default.
• W2947220160 hasAuthorship W2947220160A5061365371 @default.
• W2947220160 hasAuthorship W2947220160A5071357841 @default.
• W2947220160 hasAuthorship W2947220160A5084443648 @default.
• W2947220160 hasConcept C121608353 @default.
• W2947220160 hasConcept C126322002 @default.
• W2947220160 hasConcept C141071460 @default.
• W2947220160 hasConcept C143998085 @default.
• W2947220160 hasConcept C203092338 @default.
• W2947220160 hasConcept C2776694085 @default.
• W2947220160 hasConcept C2777546739 @default.
• W2947220160 hasConcept C2777701055 @default.
• W2947220160 hasConcept C2778822529 @default.
• W2947220160 hasConcept C2779231225 @default.
• W2947220160 hasConcept C2779984678 @default.
• W2947220160 hasConcept C2780030458 @default.
• W2947220160 hasConcept C2781433595 @default.
• W2947220160 hasConcept C31760486 @default.
• W2947220160 hasConcept C535046627 @default.
• W2947220160 hasConcept C71924100 @default.
• W2947220160 hasConcept C72563966 @default.
• W2947220160 hasConcept C90924648 @default.
• W2947220160 hasConceptScore W2947220160C121608353 @default.
• W2947220160 hasConceptScore W2947220160C126322002 @default.
• W2947220160 hasConceptScore W2947220160C141071460 @default.
• W2947220160 hasConceptScore W2947220160C143998085 @default.
• W2947220160 hasConceptScore W2947220160C203092338 @default.
• W2947220160 hasConceptScore W2947220160C2776694085 @default.
• W2947220160 hasConceptScore W2947220160C2777546739 @default.
• W2947220160 hasConceptScore W2947220160C2777701055 @default.
• W2947220160 hasConceptScore W2947220160C2778822529 @default.
• W2947220160 hasConceptScore W2947220160C2779231225 @default.
• W2947220160 hasConceptScore W2947220160C2779984678 @default.
• W2947220160 hasConceptScore W2947220160C2780030458 @default.
• W2947220160 hasConceptScore W2947220160C2781433595 @default.
• W2947220160 hasConceptScore W2947220160C31760486 @default.
• W2947220160 hasConceptScore W2947220160C535046627 @default.
• W2947220160 hasConceptScore W2947220160C71924100 @default.
• W2947220160 hasConceptScore W2947220160C72563966 @default.
• W2947220160 hasConceptScore W2947220160C90924648 @default.
• W2947220160 hasIssue "15_suppl" @default.
• W2947220160 hasLocation W29472201601 @default.
• W2947220160 hasOpenAccess W2947220160 @default.
• W2947220160 hasPrimaryLocation W29472201601 @default.
• W2947220160 hasRelatedWork W2936810997 @default.
• W2947220160 hasRelatedWork W2947220160 @default.
• W2947220160 hasRelatedWork W2947947780 @default.
• W2947220160 hasRelatedWork W2978259179 @default.
• W2947220160 hasRelatedWork W3028638056 @default.
• W2947220160 hasRelatedWork W3095042835 @default.
• W2947220160 hasRelatedWork W3166561848 @default.
• W2947220160 hasRelatedWork W4205958341 @default.
• W2947220160 hasRelatedWork W4242192132 @default.
• W2947220160 hasRelatedWork W4322604110 @default.
• W2947220160 hasVolume "37" @default.
• W2947220160 isParatext "false" @default.
• W2947220160 isRetracted "false" @default.
• W2947220160 magId "2947220160" @default.

• next